Merck's (MRK) Chronic Cough Drug Gets Another CRL From FDA
https://www.zacks.com/stock/news/2201156/merck-s-mrk-chronic-cough-drug-gets-another-crl-from-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201156
Dec 21, 2023 - Per the FDA, the data submitted by Merck (MRK) for its chronic cough drug did not provide sufficient evidence to prove its clinical benefit in patients.
0
Here's Why You Should Retain Charles River (CRL) Stock Now
https://www.zacks.com/stock/news/2209712/here-s-why-you-should-retain-charles-river-crl-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2209712
Jan 12, 2024 - Investors are optimistic about Charles River (CRL) owing to growth in the RMS and DSA segments and stable solvency position.
0
Vanda (VNDA) Falls on FDA's CRL to Hetlioz sNDA for Insomnia
https://www.zacks.com/stock/news/2237412/vanda-vnda-falls-on-fda-s-crl-to-hetlioz-snda-for-insomnia?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2237412
Mar 07, 2024 - Vanda's (VNDA) supplemental new drug application seeking approval for Hetlioz to treat insomnia gets a complete response letter from the FDA.
0
Charles River (CRL) Extends Gene Therapy Offering With New Pact
https://www.zacks.com/stock/news/2241549/charles-river-crl-extends-gene-therapy-offering-with-new-pact?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241549
Mar 15, 2024 - Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.
0
Charles River (CRL) Forges Collaboration With Ship of Theseus
https://www.zacks.com/stock/news/2253832/charles-river-crl-forges-collaboration-with-ship-of-theseus?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253832
Apr 11, 2024 - Charles River (CRL) is set to perform plasmid production for Ship of Theseus.
0
Here's Why You Should Retain Charles River (CRL) Stock Now
https://www.zacks.com/stock/news/2193393/here-s-why-you-should-retain-charles-river-crl-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2193393
Dec 05, 2023 - Charles River's (CRL) share price is likely to grow, backed by the strength of the DSA segment.
0
Charles River (CRL) Expands 3D In Vitro Services Via New Deal
https://www.zacks.com/stock/news/2197217/charles-river-crl-expands-3d-in-vitro-services-via-new-deal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2197217
Dec 13, 2023 - Charles River (CRL) finalizes agreement with service-based biotechnology company, CELLphenomics.
0
Charles River's (CRL) Memphis Site Achieves Crucial Approval
https://www.zacks.com/stock/news/2199833/charles-river-s-crl-memphis-site-achieves-crucial-approval?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2199833
Dec 19, 2023 - Charles River (CRL) reaches an important milestone in cell therapy manufacturing collaboration with Vertex Pharmaceuticals.
0
Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate
https://www.zacks.com/stock/news/2201507/pharma-stock-roundup-fda-nod-to-azn-s-eplontersen-crl-to-mrk-s-cough-candidate?cid=CS-ZC-FT-analyst_blog|stock_roundup-2201507
Dec 22, 2023 - FDA approves AstraZeneca (AZN) and Ionis' (IONS) Wainua (eplontersen) for ATTRv-PN and gives CRL to Merck's chronic cough candidate, gefapixant.
0
Unveiling Charles River (CRL) Q4 Outlook: Wall Street Estimates for Key Metrics
https://www.zacks.com/stock/news/2224019/unveiling-charles-river-crl-q4-outlook-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2224019
Feb 09, 2024 - Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
0
Pages: 12
Page 1